Download
s12913-021-06970-8.pdf 931,68KB
WeightNameValue
1000 Titel
  • A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany
1000 Autor/in
  1. Jakobs, Florian |
  2. Wingen-Heimann, Sebastian Marcel |
  3. Jeck, Julia |
  4. Kron, Anna |
  5. Cornely, Oliver Andreas |
  6. Kron, Florian |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-09-09
1000 Erschienen in
1000 Quellenangabe
  • 21(1):939
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12913-021-06970-8 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428130/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Clostridioides difficile infection (CDI) is one of the leading nosocomial infections, resulting in increased hospital length of stay and additional treatment costs. Bezlotoxumab, the first monoclonal antibody against CDI, has an 1 A guideline recommendation for prevention of CDI, after randomized clinical trials demonstrated its superior efficacy vs. placebo.!##!Methods!#!The budget impact analysis at hand is focused on patients at high risk of CDI recurrence. Treatment with standard of care (SoC) + bezlotoxumab was compared with current SoC alone in the 10 most associated Diagnosis Related Groups to identify, analyze, and evaluate potential cost savings per case from the German hospital management perspective. Based on variation in days to rehospitalization, three different case consolidation scenarios were assessed: no case consolidation, case consolidation for the SoC + bezlotoxumab treatment arm only, and case consolidation for both treatment arms.!##!Results!#!On average, the budget impact amounted to € 508.56 [range: € 424.85 - € 642.19] for no case consolidation, € 470.50 [range: € 378.75 - € 601.77] for case consolidation in the SoC + bezlotoxumab treatment arm, and € 618.00 [range: € 557.40 - € 758.41] for case consolidation in both treatment arms.!##!Conclusions!#!The study demonstrated administration of SoC + bezlotoxumab in patients at high risk of CDI recurrence is cost-saving from a hospital management perspective. Reduced length of stay in bezlotoxumab treated patients creates free spatial and personnel capacities for the treating hospital. Yet, a requirement for hospitals to administer bezlotoxumab is the previously made request for additional fees and a successful price negotiation.
1000 Sacherschließung
lokal Clostridioides difficile [MeSH]
lokal Anti-Bacterial Agents/therapeutic use [MeSH]
lokal Antibodies, Monoclonal/therapeutic use [MeSH]
lokal Humans [MeSH]
lokal Broadly Neutralizing Antibodies [MeSH]
lokal Germany
lokal Hospitals [MeSH]
lokal Risk factors
lokal Budget impact analysis
lokal Germany/epidemiology [MeSH]
lokal Recurrence [MeSH]
lokal Diagnosis Related Groups
lokal Bezlotoxumab
lokal Standard of Care [MeSH]
lokal Research
lokal Antibodies, Neutralizing [MeSH]
lokal Recurrent CDI
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/SmFrb2JzLCBGbG9yaWFu|https://frl.publisso.de/adhoc/uri/V2luZ2VuLUhlaW1hbm4sIFNlYmFzdGlhbiBNYXJjZWw=|https://frl.publisso.de/adhoc/uri/SmVjaywgSnVsaWE=|https://frl.publisso.de/adhoc/uri/S3JvbiwgQW5uYQ==|https://frl.publisso.de/adhoc/uri/Q29ybmVseSwgT2xpdmVyIEFuZHJlYXM=|https://frl.publisso.de/adhoc/uri/S3JvbiwgRmxvcmlhbg==
1000 Hinweis
  • DeepGreen-ID: 6bf2dec8896e4105b91782f505a532e5 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6463701.rdf
1000 Erstellt am 2023-11-15T20:21:29.839+0100
1000 Erstellt von 322
1000 beschreibt frl:6463701
1000 Zuletzt bearbeitet 2023-11-30T22:10:07.125+0100
1000 Objekt bearb. Thu Nov 30 22:10:07 CET 2023
1000 Vgl. frl:6463701
1000 Oai Id
  1. oai:frl.publisso.de:frl:6463701 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source